🔧 They will install a new AST GENiSYS® C automated fill/finish line in the coming year.
💉 This line will assist in producing sterile injectables, especially for high-value drugs and rare diseases.
📈 The addition enhances flexibility and scalability, meeting increasing demand in the pharmaceutical industry.
🏢 Bora’s facility specializes in various drug manufacturing services.
Introduction:
The article discusses Bora Pharmaceuticals’ plan to enhance its sterile fill/finish capacity by adding a new automated line at its Baltimore facility. This initiative reflects the growing demand for drug product manufacturing, particularly for high-value substances and treatments for rare diseases.
- Bora Pharmaceuticals is installing an AST GENiSYS® C automated fill/finish line, which is expected to be operational over the next year.
- The new line will operate under full isolator conditions and is designed for clinical and small-scale commercial supply.
- Increasing demand for fill and finish services is noted, particularly for potent drug candidates and therapies for rare diseases.
- The new line will enhance Bora’s overall capacity while complementing existing large-scale manufacturing operations, thus improving flexibility and scalability.
- Bora’s Baltimore facility provides a range of drug manufacturing services, including aseptic fill/finish processes, lyophilization, and packaging.
Conclusion:
Bora Pharmaceuticals’ installation of the AST GENiSYS® C line is a strategic response to rising market demands for customized fill/finish services. This advancement not only expands their manufacturing capabilities but also positions the company to better address specific public health needs associated with rare and potent medications. The integration of the new line is expected to significantly contribute to Bora’s operational flexibility in the growing biopharmaceutical sector.